Clinical trial
Ph II Study of Perifosine Plus Gleevec for Patients With GIST
NCT00455559 · AEterna Zentaris, Industry · Completed
Key facts
| NCT number | NCT00455559 |
|---|---|
| Title | Ph II Study of Perifosine Plus Gleevec for Patients With GIST |
| Official title | A Phase II Study of Perifosine Plus Imatinib Mesylate for Patients With Resistant Gastrointestinal Stromal Tumor |
| Lead sponsor | AEterna Zentaris, Industry |
| Collaborators | M.D. Anderson Cancer Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumors |
| Intervention type | Drug |
| Interventions | Perifosine, Imatinib Mesylate |
| Enrollment | 40 |
| Start date | Aug 1, 2006 |
| Primary completion | Nov 1, 2010 |
| Completion | Oct 1, 2011 |
| First posted | Apr 3, 2007 |
| Last update posted | Feb 22, 2018 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: